Lotemax loteprednol etabonate: Completed Phase III trial, and expects to submit an NDA this month

Pharmos Corp. (PARS), New York Product: Lotemax loteprednol etabonate, ophthalmic anti-inflammatory Indication: Uveitis Status: Completed Phase III trial, and expects to submit an NDA this month ...